Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L B Grochow

Showing results (51-60 of 85) with videos related to

Pageof 9
Sort By:
Cancer Chemotherapy and Pharmacology|January 1, 1989
Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantationL B Grochow, R J Jones, R B Brundrett, et al.
American Journal of Surgery|January 1, 1990
Preoperative assessment of malignant hepatic tumorsJ V Sitzmann, J Coleman, H A Pitt, et al.
Cancer Research|November 1, 1991
Phase I and pharmacokinetic study of hepsulfam (NSC 329680)C B Hendricks, L B Grochow, E K Rowinsky, et al.
Cancer Investigation|August 3, 2000
A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancerE C Dees, S O'Reilly, S N Goodman, et al.
Journal of the National Cancer Institute|January 18, 1989
Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamicsL B Grochow, D A Noe, G B Dole, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1996
Phase I and pharmacologic study of topotecan in patients with impaired renal functionS O'Reilly, E K Rowinsky, W Slichenmyer, et al.
Cancer Research|December 1, 1987
Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumorsW P Peters, W D Henner, L B Grochow, et al.
Cancer Research|June 1, 1990
Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazoleA Hantel, R C Donehower, E K Rowinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 1997
Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removalA A Adjei, I I Budihardjo, E K Rowinsky, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 1, 1992
Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancerL B Grochow, E K Rowinsky, R Johnson, et al.
Pageof 9

Showing results (51-60 of 85) with videos related to

Sort By:
Pageof 9
Cancer Chemotherapy and Pharmacology|January 1, 1989
Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantationL B Grochow, R J Jones, R B Brundrett, et al.
American Journal of Surgery|January 1, 1990
Preoperative assessment of malignant hepatic tumorsJ V Sitzmann, J Coleman, H A Pitt, et al.
Cancer Research|November 1, 1991
Phase I and pharmacokinetic study of hepsulfam (NSC 329680)C B Hendricks, L B Grochow, E K Rowinsky, et al.
Cancer Investigation|August 3, 2000
A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancerE C Dees, S O'Reilly, S N Goodman, et al.
Journal of the National Cancer Institute|January 18, 1989
Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamicsL B Grochow, D A Noe, G B Dole, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1996
Phase I and pharmacologic study of topotecan in patients with impaired renal functionS O'Reilly, E K Rowinsky, W Slichenmyer, et al.
Cancer Research|December 1, 1987
Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumorsW P Peters, W D Henner, L B Grochow, et al.
Cancer Research|June 1, 1990
Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazoleA Hantel, R C Donehower, E K Rowinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 1997
Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removalA A Adjei, I I Budihardjo, E K Rowinsky, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 1, 1992
Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancerL B Grochow, E K Rowinsky, R Johnson, et al.
Pageof 9